GlassScriptPhysician profile
Sohail Akbani
NPI 1134121668
$10,331.39
in general payments reported to CMS, 2019-2025
62 companies · $25.23 in 2025
The $25.23 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,132 · 2020: $3,288 · 2021: $312 · 2022: $1,667 · 2023: $1,739 · 2024: $1,169 · 2025: $25.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.96 |
| Education | $383.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,003.65 | 2019-2024 | Calquence, Enhertu, Imfinzi |
| Pfizer INC. | $670.30 | 2019-2024 | |
| Astellas Pharma US INC | $471.01 | 2019-2024 | Xtandi, Padcev |
| E.R. Squibb & Sons, L.L.C. | $431.27 | 2019-2023 | Opdivo |
| Incyte Corporation | $425.48 | 2019-2024 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $423.70 | 2019-2024 | |
| Janssen Biotech, INC. | $317.36 | 2019-2023 | Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $303.27 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $218.86 | 2019-2024 | |
| Glaxosmithkline, LLC. | $217.45 | 2020-2024 | Ojjaara |
| Seagen INC. | $216.80 | 2022-2023 | Adcetris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.99 | 2019-2023 | Gilotrif |
| Celgene Corporation | $206.70 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $202.78 | 2019-2024 | Trodelvy |
| Genzyme Corporation | $197.22 | 2019-2024 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.01 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Genentech USA, INC. | $175.02 | 2019-2024 | Tecentriq, Alecensa, Polivy |
| Aveo Pharmaceuticals, INC. | $165.94 | 2022-2023 | Fotivda |
| Jazz Pharmaceuticals INC. | $152.15 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $151.94 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $124.31 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $112.61 | 2019-2024 | Enhertu, Injectafer |
| Abbvie INC. | $108.08 | 2019-2024 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $104.46 | 2019-2023 | Libtayo |
| Emd Serono, INC. | $101.86 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Rigel Pharmaceuticals, INC. | $94.70 | 2019-2023 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $87.30 | 2019-2024 | Fruzaqla, Ninlaro |
| Dendreon Pharmaceuticals LLC | $81.73 | 2019-2024 | Provenge |
| Teva Pharmaceuticals USA, INC. | $73.04 | 2019 | |
| Beigene USA, INC. | $71.56 | 2022-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $63.23 | 2019-2023 | |
| Puma Biotechnology, INC. | $60.51 | 2019-2023 | |
| Exelixis INC. | $59.51 | 2021-2023 | Cabometyx |
| Ortho-Clinical Diagnostics, INC. | $50.97 | 2019 | |
| Sirtex Medical INC | $48.63 | 2023-2025 | Sir-Spheres Microspheres |
| Myovant Sciences INC. | $43.48 | 2022 | |
| Array Biopharma INC | $38.64 | 2021-2022 | |
| Taiho Oncology, INC. | $38.46 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $38.18 | 2023-2024 | Xpovio |
| Siemens Medical Solutions USA, INC. | $37.13 | 2022 | |
| Genmab U.S., INC. | $36.19 | 2024 | Epkinly, Tivdak |
| Clovis Oncology, INC. | $35.78 | 2019 | |
| Adaptive Biotechnologies Corporation | $27.40 | 2021 | |
| Kite Pharma, INC. | $26.97 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.05 | 2024 | Qinlock |
| Boston Scientific Corporation | $22.69 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Secura Bio, INC. | $22.18 | 2020-2022 | |
| Csl Behring | $21.74 | 2022 | |
| Morphosys, US INC. | $20.53 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $19.72 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $19.59 | 2022 | |
| Tesaro, INC. | $19.13 | 2019 | |
| Tersera Therapeutics LLC | $18.88 | 2023 | Xermelo |
| Shield Therapeutics INC | $18.36 | 2023 | Accrufer |
| Helsinn Therapeutics (U.S.), INC. | $18.23 | 2019 | |
| Foundation Medicine, INC. | $17.83 | 2019 | |
| Dova Pharmaceuticals | $15.86 | 2020 | |
| Fennec Pharmaceuticals, INC. | $14.84 | 2024 | Pedmark |
| Sun Pharmaceutical Industries INC. | $14.69 | 2024 | |
| Eagle Pharmaceuticals, INC. | $14.60 | 2020 | |
| Mylan Institutional INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Akbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.